Gilead Sciences to acquire HDV drug developer MYR in €1.4bn deal
Gilead Sciences acquisition of MYR : US biopharma giant Gilead Sciences has agreed to acquire MYR, a German biotech company engaged in developing therapies for chronic hepatitis delta virus (HDV), in a deal worth up to €1.45 billion. The consideration consists of nearly €1.15 billion in cash, which will be paid at the time of […]